Modelling long-term outcomes for patients with systemic lupus erythematosus

This publication has 39 references indexed in Scilit:

• Clinical disease activity and flare in SLE: Current concepts and novel biomarkers
  Journal of Autoimmunity, 2021
• Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty‐Two–Week Randomized, Double‐Blind, Placebo‐Controlled Study
  Arthritis & Rheumatology, 2017
• Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double‐Blind, Placebo‐Controlled Trials
  Arthritis & Rheumatology, 2016
• The Systemic Lupus International Collaborating Clinics (SLICC) damage index: A systematic literature review
  Seminars in Arthritis and Rheumatism, 2013
• Cumulative Burden of Oral Corticosteroid Adverse Effects and the Economic Implications of Corticosteroid Use in Patients With Systemic Lupus Erythematosus
  Clinical Therapeutics, 2013
• Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
  The Lancet, 2011
• Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: The randomized, double‐blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial
  Arthritis & Rheumatism, 2009
• Contributions of Observational Cohort Studies in Systemic Lupus Erythematosus: The University of Toronto Lupus Clinic Experience
  Rheumatic Disease Clinics of North America, 2005
• A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68)
  Diabetologia, 2004
• The development and initial validation of the systemic lupus international collaborating clinics/American college of rheumatology damage index for systemic lupus erythematosus
  Arthritis & Rheumatism, 1996